Stocks & Investing
Fri, August 9, 2024
[ Fri, Aug 09th 2024
] - WOPRAI
Fri, August 2, 2024
[ Fri, Aug 02nd 2024
] - WOPRAI
Thu, April 4, 2024
[ Thu, Apr 04th 2024
] - WOPRAI
Tue, April 2, 2024
[ Tue, Apr 02nd 2024
] - WOPRAI
Mon, February 12, 2024
Thu, January 4, 2024
[ Thu, Jan 04th 2024
] - WOPRAI
Thu, July 6, 2023
[ Thu, Jul 06th 2023
] - WOPRAI
Wed, March 29, 2023
[ Wed, Mar 29th 2023
] - WOPRAI
Fri, March 3, 2023
[ Fri, Mar 03rd 2023
] - WOPRAI
Tue, June 28, 2022
[ Tue, Jun 28th 2022
] - WOPRAI
Tue, December 21, 2021
[ Tue, Dec 21st 2021
] - WOPRAI
Roy Buchanan Maintained (ANTX) at Buy with Decreased Target to $3 on, Aug 9th, 2024
Roy Buchanan of JMP Securities, Maintained "AN2 Therapeutics, Inc." (ANTX) at Buy with Decreased Target from $6 to $3 on, Aug 9th, 2024.
Roy has made no other calls on ANTX in the last 4 months.
There are 2 other peers that have a rating on ANTX. Out of the 2 peers that are also analyzing ANTX, 1 agrees with Roy's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Liisa Bayko of "Evercore ISI Group" Maintained at Hold with Decreased Target to $2 on, Thursday, May 16th, 2024
This is the rating of the analyst that currently disagrees with Roy
- Joseph Schwartz of "Leerink Partners" Upgraded from Hold to Buy on, Wednesday, July 3rd, 2024
